PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
MNPR vs. CALX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between MNPR and CALX is 0.11, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

MNPR vs. CALX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Monopar Therapeutics Inc. (MNPR) and Calix, Inc. (CALX). The values are adjusted to include any dividend payments, if applicable.

0.00%500.00%1,000.00%1,500.00%2,000.00%SeptemberOctoberNovemberDecember2025February
2,100.00%
12.56%
MNPR
CALX

Key characteristics

Sharpe Ratio

MNPR:

5.11

CALX:

0.58

Sortino Ratio

MNPR:

10.00

CALX:

1.11

Omega Ratio

MNPR:

2.39

CALX:

1.13

Calmar Ratio

MNPR:

32.88

CALX:

0.35

Martin Ratio

MNPR:

77.20

CALX:

1.84

Ulcer Index

MNPR:

42.07%

CALX:

12.48%

Daily Std Dev

MNPR:

637.60%

CALX:

39.40%

Max Drawdown

MNPR:

-98.93%

CALX:

-80.95%

Current Drawdown

MNPR:

-61.56%

CALX:

-47.89%

Fundamentals

Market Cap

MNPR:

$295.73M

CALX:

$2.72B

EPS

MNPR:

-$2.04

CALX:

-$0.44

Total Revenue (TTM)

MNPR:

$0.00

CALX:

$625.39M

EBITDA (TTM)

MNPR:

-$1.58B

CALX:

-$9.48M

Returns By Period

In the year-to-date period, MNPR achieves a 135.86% return, which is significantly higher than CALX's 19.50% return.


MNPR

YTD

135.86%

1M

104.69%

6M

2,103.40%

1Y

2,865.14%

5Y*

-4.66%

10Y*

N/A

CALX

YTD

19.50%

1M

14.76%

6M

12.56%

1Y

20.29%

5Y*

33.21%

10Y*

17.08%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

MNPR vs. CALX — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MNPR
The Risk-Adjusted Performance Rank of MNPR is 100100
Overall Rank
The Sharpe Ratio Rank of MNPR is 100100
Sharpe Ratio Rank
The Sortino Ratio Rank of MNPR is 100100
Sortino Ratio Rank
The Omega Ratio Rank of MNPR is 9999
Omega Ratio Rank
The Calmar Ratio Rank of MNPR is 100100
Calmar Ratio Rank
The Martin Ratio Rank of MNPR is 100100
Martin Ratio Rank

CALX
The Risk-Adjusted Performance Rank of CALX is 6262
Overall Rank
The Sharpe Ratio Rank of CALX is 6666
Sharpe Ratio Rank
The Sortino Ratio Rank of CALX is 6161
Sortino Ratio Rank
The Omega Ratio Rank of CALX is 5858
Omega Ratio Rank
The Calmar Ratio Rank of CALX is 6262
Calmar Ratio Rank
The Martin Ratio Rank of CALX is 6565
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

MNPR vs. CALX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Monopar Therapeutics Inc. (MNPR) and Calix, Inc. (CALX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for MNPR, currently valued at 5.11, compared to the broader market-2.000.002.004.005.110.58
The chart of Sortino ratio for MNPR, currently valued at 10.00, compared to the broader market-4.00-2.000.002.004.0010.001.11
The chart of Omega ratio for MNPR, currently valued at 2.39, compared to the broader market0.501.001.502.002.391.13
The chart of Calmar ratio for MNPR, currently valued at 32.88, compared to the broader market0.002.004.006.0032.880.35
The chart of Martin ratio for MNPR, currently valued at 77.20, compared to the broader market0.005.0010.0015.0020.0025.0030.0077.201.84
MNPR
CALX

The current MNPR Sharpe Ratio is 5.11, which is higher than the CALX Sharpe Ratio of 0.58. The chart below compares the historical Sharpe Ratios of MNPR and CALX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.004.005.00SeptemberOctoberNovemberDecember2025February
5.11
0.58
MNPR
CALX

Dividends

MNPR vs. CALX - Dividend Comparison

Neither MNPR nor CALX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

MNPR vs. CALX - Drawdown Comparison

The maximum MNPR drawdown since its inception was -98.93%, which is greater than CALX's maximum drawdown of -80.95%. Use the drawdown chart below to compare losses from any high point for MNPR and CALX. For additional features, visit the drawdowns tool.


-100.00%-90.00%-80.00%-70.00%-60.00%-50.00%SeptemberOctoberNovemberDecember2025February
-61.56%
-47.89%
MNPR
CALX

Volatility

MNPR vs. CALX - Volatility Comparison

Monopar Therapeutics Inc. (MNPR) has a higher volatility of 41.98% compared to Calix, Inc. (CALX) at 13.46%. This indicates that MNPR's price experiences larger fluctuations and is considered to be riskier than CALX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%50.00%100.00%150.00%200.00%SeptemberOctoberNovemberDecember2025February
41.98%
13.46%
MNPR
CALX

Financials

MNPR vs. CALX - Financials Comparison

This section allows you to compare key financial metrics between Monopar Therapeutics Inc. and Calix, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab